natgillin/translations-raw huggingface dataset:
Suitable adjuvants include, but are not limited to, 1018 ISS, aluminum salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod (ALDARA), resimiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13, IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, JuvImmune, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system, PLG and dextran microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. 
Farmaceutski sastav prema zahtjevu 1 ili 2, gdje najmanje jedan peptid uključuje nepeptidne veze. Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta. Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 4, koji nadalje uključuje najmanje jedan prikladan adjuvans odabran iz skupine koja sadrži 1018 ISS, aluminijeve soli, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, imikvimod, ImuFact IMP321, IS Patch, ISCOMATRIX, JuvImmune, LipoVac, MFS59, monofosforilni lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, vektorski sustav PepTel, PLG mikro-čestice, resikvimod, SRL172, Virosomes 1 druge čestice slične virusima, YF-17DBCG, stimulon QS21 kompanije Aquila Biotech, Ribi's Detox.
and wherein the conjugating occurs under conditions where n is an integer from 1 to 20. 
D obuhvaća citotoksično sredstvo; i n je cijeli broj od 1 do 20.
reaction of a compound of Formula (6) with a compound of Formula (7): wherein X' is a leaving group; or 
(5) pri čemu X je odlazna skupina; ili C) reakciju spoja formule (6) sa spojem formule (7):
<400> 54 Oligonucleotide sequence characterized in that it increases the transcription rate of a RNA typed as messenger RNA fragment encoding for a protein selected from the group consisting of enzymes, structural proteins, coenzymes, transporters, antibodies, hormones and regulators, as regulatory RNA fragment, as enzymatically active RNA fragment or as transfer RNA fragment, said oligonucleotide sequence having at least 80% sequence identity to SEQ ID NO: 1. 
Obigonukleotidna sekvenca naznačena fime da povećava razinu transkripcije DNA klasificirane kao glasnički DNA fragment koji kodira za protein iz grupe koja sadrži enzime, strukturalne proteine, koenzime, transporine proteine, antitijola, hormone i regulatore, kao regulirajući DNA fragment, kao enzimski aktivan DNA fragment ili kao prijenosni DNA fragment, ako je oligonukleotidna sekvenca najmanje 80% identična sekvenci SEQ ID No:1.
at least one device for moving (1, 1') according to any of the previous claims; where the furniture frame (4) defines a containment compartment (34) which, in the rest configuration, houses the movement device (1, 1'). 
- < najmanje jedan uređaj (1, 1) za pomicanje prema bilo kojem od prethodnih zahtjeva; pri čemu postolje (4) namještaja definira komoru (34) sanduka za odlaganje koji u konfiguraciji za ležanje prihvaća pomicanje uređaja (1, 1%).
(b8) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 129, 130, and 131 (H chain CDRs of J339), respectively; 
(b8) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1,21 3 od SEQ ID NO: 129, 130 odnosno 131 (H-lanac CDR-područja od J339);
separating, and optionally drying, the solid ligand-modified poly oxo-hydroxy metal ion material produced in step (b). 
odvajanje, i po želji sušenje, krutog materijala poli-okso-hidroksi-metalnih iona modificiranog ligandima, koji se proizvodi u koraku (b).
and racemic compounds of formula Ib (anti) 
CH, i racemičkih spojeva sa formulom Ib (anti)
The terminal apparatus according to one of claims 1-2, wherein the number of available bits is determined based on a system bandwidth. A receiving method comprising: 
Uređaj za prijenos prema jednom od zahtjeva 1 do 7, naznačen time da se broj raspoloživih bitova u polju dodjele resursa određuje na osnovi propusne širine sustava.
WO 2004/100897 A, published on 25.11.2004, discloses a process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin. 
Dokument WO 2004/100897 A, objavljen 25.11.2004., otkriva postupak dobivanja 7-alkil-10-hidroksi-20(S)- kamptotecina.
fractions A and B of the virgin Ziegler-Natta catalyzed polyethylene resin are prepared in at least 2 reactor. 
- Frakcije A 1 B neobrađene Ziegler-Natta katalizirane polietilenske smole su pripravljene u minimalno 2 reaktora i to poželjno u serijama.
A paper product according to paragraph 1 which is coated with a paper coating composition, where the coated paper product has a first gloss greater than a second gloss of the coated paper product devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition. 
Papirni proizvod u skladu s patentnim zahtjevom 8, naznačen time što ima prvi sjaj veći od drugog sjaja obloženog papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala.
The process of claim 11 or claim 12, comprising exchanging heat from the exhaust gas through a heat exchanger to water in a hot water loop, and transferring heat in the water through the hot water loop to a local community. 
Postupak sukladno patentnom zahtjevu 11 ili patentnom zahtjevu 12, naznačen time da, uključuje izmjenu topline iz ispušnog plina kroz izmjenjivač topline u vodi u petlji s toplom vodom, i prijenos topline u vodi kroz petlju s toplom vodom do lokalne zajednice.
or a pharmaceutically acceptable salt form thereof. The compound of claim 1, wherein n and m are 1 or 2 or wherein X is absent and L is preferably C1-4alkylene and more preferably selected from the group consisting of -CH2-, -CH2-CH2-, -CH2-CH2CH2-, and -CH2-CH2CH2CH2- or L is or and preferably 
ili njegov farmaceutski prihvatljiv solni oblik, naznačen time što dodatno n i m je 2, ili X je odsutan, a L je, ili predstavlja, ili X je -CH2-, a L je -S-C1-4alkilen, -S(O)2-C1-4alkilen ili -O-C(O)-C1-4alkilen, ili X je S, ili svaki od R1 i R2 je C10-18alkil.
iii) transforming a compound of formula (V) into the corresponding nitrile derivative of formula (VI) 
pretvorba spoja formule (V) u odgovarajući nitrilni derivat spoja formule (VI), [image]
a second intermediate spacing layer (12, 112, 212, 412), which is substantially hydrophobic and transfers the liquid-phase perspiration from said first inner layer (11, 111, 211, 411) toward a third outer layer (13, 113, 213), 
- < drugog međusloja za održavanje razmaka (12, 112, 212, 412), koji je u biti hidrofoban 1 prenosi tekuću fazu znoja 1z prvog unutarnjeg sloja (11, 111,211, 411) prema trećem vanjskom sloju (13, 113, 213),
with a difference in protective capacity (Apc) between the functional variant and the placebo (negative) control of at least 50%, especially at least 60%, preferably at least 70%, more preferably at least 80%, even more preferably 90%, even more preferably 95%, most preferably at least 95%. 
s razlikom u zaštitnom kapacitetu (Apc) između funkcionalne varijante i placebo (negativne) kontrole od najmanje 50%, posebno najmanje 60%, poželjno najmanje 70%, više preferirano najmanje 80%, čak još bolje najmanje 90%, čak i više poželjno najmanje 95%, najpoželjnije najmanje 95%.
Nifuratel for use according to claim 8, characterized in that said at least one antibiotic is selected from: clindamycin, macrolide antibiotics such as erythromycin, oleandomycin, flurithromycin, azithromycin and claritromycin and salts thereof, beta-lactam antibiotics such as penicillin, ampicillin, amoxicillin and salts thereof, fluoroquinolones such as ofloxacine, norfloxacine, ciprofloxacine and salts thereof, aminoglycosides such as gentamycin, amikacin, kanamycin, neomycin and salts thereof. 
Nifuratel, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan antibiotik bira između: klindamicina, makrolidnih antibiotika, poput eritromicina, oleandomicina, fluritromicina, azitromicina i klaritromicina i njihovih soli, B-laktamskih antibiotika, poput penicilina, ampicilina, amoksicilina i njihovih soli, fluorkinolona, poput ofloksacina, norfloksacina, ciprofloksacina i njihovih soli, aminoglikozida, poput gentamicina, amikacina, kanamicina, neomicina i njihovih soli.
The use of claim 4, wherein the cancers or tumors are induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof. 
Uporaba u skladu s patentnim zahtjevom 4, naznačena time, da su rak ili tumor inducirani receptorom epidermalnog receptora faktora rasta (EGFR) tirozin kinaze ili njegovog mutanta.
A compound according to claim 1 being selected from: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupa koji čine:
In a preferred embodiment of the invention, the forward and reverse primers used in the amplification of the nucleic acid sample may contain within a longer sequence or comprise solely of the following sequences or a fragment thereof: Forward primer: 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što početnice koje se upotrebljava za amplificiranje uzorka nukleinske kiseline mogu u sebi sadržavati dulji slijed ili se sastojati samo od sljedećih sljedova ili njihovih fragmenata: početnice prema naprijed: 5'-GAGCTAACCGGAGAGGGAGA-5' početnice prema natrag: 5'-CGCATACCGACTTTCGTCAA-5".
The T cell activating bispecific antigen-binding molecule of claim 14, wherein in the second subunit of the Fc domain the threonine residue at position 366 is replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A) (EU numbering). 
u drugoj podjedinici Fc domene ostatak treonina na položaju 366 dodatno zamijenjen ostatkom serina (T366S) i ostatak leukina na položaju 368 zamijenjen ostatkom alanina (L368A); i/ili
reacting a compound of the formula II A-(CH2)m-X II wherein A is as defined in claim 1, m is 0, 1 or 2 and X is a leaving group, with a compound of the formula III wherein Z, n, R2, R3 and R4 are as defined in claim 1; 
(a) reakcija spoja formule II A-(CH2)m-X I gdje A je kao definiran u zahtjevu 1, mje 0, 1 ili 21 X je izlazeća skupina, sa spojem formule III
The antibody, conjugate or pharmaceutical composition of claim 16 wherein the disease or disorder is a tumor-related disease, preferably selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer and hepatocellular cancer. 
Antitijelo za primjenu iz patentnog zahtjeva 14 konjugat za primjenu iz patentnog zahtjeva 14 ili farmaceutska kompozicija za primjenu iz patentnog zahtjeva 14 gdje bolest ili poremećaj je odabran iz grupe koja se sastoji od raka dojke, raka pluća, raka želuca, raka jajnika i hepatocelularnog raka.
The method according to claim 11, wherein the composition is a gel, spray, ointment, cream or patch for transdermal use and it comprises 0.1-1000 mg/ml of MK-467 and 0.01-500 mg/ml of the a2-adrenoceptor agonist. 
MK-467 za medicinsku upotrebu kod pacijenta kojem je potrebna sedacija prema bilo kojem patentnom zahtjevu 11-16, naznačen time da je pripravak gel, sprej, mast, krema ili flaster za transdermalnu upotrebu i da sadrži 0.1-1000 mg/ml MK-467 i 0.01-500 mg/ml agonista a2- adrenoceptora.
Preferred compounds of formula (I) as defined in embodiment 1) are selected from the group consisting of: 
Spoj formule (I) prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
The method of claim 1 wherein the reference B chain is contained within a single chain HGF polypeptide. 
Postupak prema zahtjevu 1, naznačen time, da se usporedbeni B lanac nalazi unutar jednolančanog HGF polipeptida.
A protection system should not rely on manual intervention by the user, to assure the greatest reliability. 
Zaštitni sustav se ne bi trebao oslanjati na ručnu intervenciju korisnika, kako bi se osigurala najveća pouzdanost.
a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence of H5; 
slijed aminokiselina najmanje 80% identičan slijedu SEQ ID NO:361;
is cyclohexyl, phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal or LA, in Subformula 12 is Hal, LA, O(LA), CN, CONH2, or a monocyclic aliphatic or aromatic homo- or heterocycle having 0, 1 or 2 N or O atoms and 5 or 6 skeleton atoms, 
R' je cikloheksil, fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal ili LA, u Podformuli 6 R' je Hal, LA, O(LA), CN, CONH_, ili monociklički alifatski ili aromatski homo- ili heterocikal koji ima 0,1 ili 2 N ili O atoma i 5 ili 6 skeletnih atoma,
or a pharmaceutically acceptable salt thereof. 
< ili njegova farmaceutski prihvatljiva sol.
A developer supply container according to claim 1, wherein the drive converting portion converts the rotational force so that an internal pressure of the developer discharging chamber changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 1 ili 2, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da se unutarnji tlak u navedenoj komori za ispuštanje Tazvijača (3h) mijenja između tlaka nižeg od tlaka okoliša i tlaka višeg od tlaka okoliša.
The method as claimed in claim 12, wherein the liquid substance is exposed to IR light or heated. 
Postupak prema zahtjevu 10, naznačen time što je tekuća supstanca bazirana na vodi i sadrži glikol ili glicerin.
The slurry of claim 1 or 2 wherein the aluminum or aluminum alloy powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 3.9 to 4.5 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Gusta smjesa iz patentnog zahtjeva 1 ili 3, pri čemu aluminij ili prah aluminijeve slitine obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 1 4.5 mikrometara (mikrona) i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.
iv-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 205 ng/ml +/- 47 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described study), and/or 
Vildagliptina od 205 ng/mL +/- 47 ng/mL nakon oralne primjene navedenog dozirnog oblika pacijentu koji nije bio tretiran vildagliptinom prije navedene primjene i pri čemu je pacijent pod uvjetima posta, i/ili kruti oralni dozirni oblik koji sadrži oko 100 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost Cmax.
a controller configured to operate the tip and to determine whether sufficient tip contact has been made with the epithelium for effective treatment; and a display configured to display a map indicating contact status of the tip with the epithelium. 
naznačen time, što je kontroler konfiguriran da upravlja vrhom i odredi je li uspostavljen dovoljan kontakt vrha s epitelom i zaslon konfiguriran za prikaz karte koja ukazuje na status kontakta vrha s epitelom.
The compound from claim 1 selected from the group consisting of: A pharmaceutical composition comprising: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran iz skupine koju čine: 2
An anti-FcRn antibody or FcRn-binding fragment thereof as defined in any one of claims 1 to 9 or a composition as defined in claim 14, for use in the treatment of CIDP, paraproteinemic polyneuropathy, refractory epilepsy, hemolytic anemia, Goodpasture's syndrome, ABO mismatch, lupus nephritis, renal vasculitis, scleroderma, fibrosing alveolitis, dilated cardiomyopathy, Grave's disease, type 1 diabetes, auto-immune diabetes, pemphigus, anca vasculitis, dermatomyositis, Sjogren's disease or rheumatoid arthritis. 
Antitijelo ili njegov vezujući fragment kako je definirano u bilo kojem patentnom zahtjevu od 1 do 12 ili pripravak kako je definirano u patentnom zahtjevu 18 ili 19, za primjenu u liječenju kronične upalne demijelinacijske polineuropatije (CIDP), paraproteinemičke polineuropatije, refraktorne epilepsije, hemolitičke anemije, Goodpastureovog sindroma, nekompatibilnosti krvnih grupa ABO, lupusnog nefritisa, bubrežnog vaskulitisa, sklerodermije, fibroznog alveolitisa, dilatirane kardiomiopatije, Graveove bolesti, dijabetesa tipa 1, autoimunog dijabetesa, pemfigusa, ANCA-pozitivnog vaskulitisa, dermatomiozitisa, Sjorgenove bolesti i reumatoidnog artritisa.
No toxicity symptom was observed in the crop at the highest dose. It is therefore concluded that AFS at a dosage of 15 mL/L is a formulation suitable for the control of Botrytis cinerea in tomatoes. A pure culture of Bacillus velezensis strain AH2, CECT-7221, and mutants thereof, having antifungal activity by producing antagonist substances, having the capability of solubilizing phosphates, of producing indole-3-acetic acid and of producing siderophores, as well as growing on 1-aminocyclopropane-1-carboxylic acid (ACC) as a sole nitrogen source. 
Čista kultura soja nazvanog AH2 vrste Bacillus velezensis, kao i njegovi mutanti, naznačena time što imaju visoku antifungalnu aktivnost i naročito protiv fitopatogenih gljivica s obzirom na njihov kapacitet za proizvodnju antagonističkih supstanci, kao 1 dobar kapacitet za stimuliranje rasta biljaka, koji soj je sposoban otapati fosfate, proizvoditi indol-3-octenu kiselinu i siderofore, kao i sposobnost stvaranja 1-aminociklopropan-1-karboksilne kiseline (ACC) kao isključivog izvora dušika, koji soj je deponiran kod Spanish Type Culture Collection (CECT) pod brojem CECT-7221.
A composition according to any of the preceding claims, wherein the component d) is selected from sulphated amino acids and derivatives thereof, 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid and/or methylsulphonylmethane. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da je sastojak d) odabran između aminokiselina koje sadrže sumpornu grupu i njihovih derivata, 1-metionina, 1-cisteina, 1-cistina, taurina, 4-tiazilidinkarboksilne kiseline i/ili metilsulfonilmetana.
1 shows the general structure of the oil well and a surface device 20 at daylight level 1 (which contains the surface ultrasonic generator 3 and the daylight surface high frequency generator 10) and the ultrasonic magnetostrictive radiator 4 at the end of the oil well tubing 5, connected by the three-cord electrical cable 9 . 
Slika 1 prikazuje općenitu strukturu naftnog izvora i površinski uređaj 20 na razni danjeg svjetla 1 (koji sadrži površinski ultrazvučni generator 3 1 površinski (na danjem svjetlu) generator visoke frekvencije 10) i ultrazvučni magnetostriktivni radijator 4 na kraju cjevovoda naftnog izvora 5, povezane trožičnim električnim kablom 9. HR P20080384 T3
Accordingly, the present invention provides an anti-FcYRIIB antibody which comprises in its heavy chain variable region an H-CDR1 sequence which is 60% or more identical to the H-CDR1 sequence shown in SEQ ID NO. 
HR P20180664 T1 PATENTNI ZAHTJEVI Protutijelo protiv FcyRIIB, naznačeno time što sadrži (i) slijed H-CDRI, koji je 60% ili više istovjetan slijedu H-CDR1 prikazanom u SEQ ID NO.
The mixture obtained was diluted with 1.51 methanol and the NaCl precipitate was removed by filtration. 
Dobivena smjesa se Tazrijedi s 1,5 1 metanola i NaCl precipitat se odstrani filtracijom.
EP577303; European Patent Application No. 
Datum podnošenja europske prijave patenta:
a triggering and determining module, configured to trigger reporting of a first power headroom report, and determine that a condition of sending the first power headroom report is satisfied, wherein the condition of sending the first power headroom report comprises: determining that uplink data channel transmission occurs in a current transmission time interval; 
modul za pokretanje i određivanje (401), konfiguriranu za pokretanje izvještavanja o prvom izvješću o zadržanoj snazi, te određivanje da je zadovoljen uvjet za slanje prvog izvješća o zadržanoj snazi, pri čemu uvjet za slanje prvog izvješća o zadržanoj snazi sadrži: određivanje da se prijenos uzlazne veze kanala podataka odvija u trenutnom vremenskom intervalu za prijenos;
in which R1 has the meaning indicated in Claim 1, and/or a base or acid of the formula I is converted into one of its salts. 
R'-NH>V u kojoj R' ima značenje navedeno u zahtjevu 1, i/ili baza ili kiselina formule I se prevodi u jednu od njezinih soli..
Apparatus for treating water at low cost, which eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the system comprising: 
Metoda za tretiranje vode niskih troškova te za korištenje nizvodno od industrijskog postupka (2), koja pročišćava vodu i uklanja otopljene čvrste čestice u vodi filtriranjem male frakcije ukupnog volumena vode, metoda obuhvaća:
The residue was purified by preparative reverse-phase high performance liquid chromatography ("HPLC"). 
Suhi ostatak je pročišćen preparativnom reverzno-faznom tekućinskom kromatografijom visoke djelotvornosti ("HPLC").
A method of inhibiting growth and/or killing of a cell expressing CLD18, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 22 and/or a conjugate of claim 25 or 26. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 za uporabu u metodi za inhibiranje rasta i/ili ubijanje stanice koja izražava CLD18A2.
THE ROBOTIC ARTICULATED TELESCOPIC ARM, according to claims 2 and 3, characterised in that the fourth hydraulic cylinder for longitudinal adjustment of the second articulated telescopic segment and the fifth hydraulic cylinder for longitudinal adjustment of the third telescopic articulated segment, are integrated and protected inside a tubular structure. 
ROBOTSKA UZGLOBLJENA TELESKOPSKA RUKA, u skladu s patentnim zahtjevima 2 i 3, naznačena time što su četvrti hidraulični cilindar za uzdužno podešavanje drugog uzglobljenog teleskopskog segmenta i peti hidraulični cilindar za uzdužno podešavanje trećeg teleskopskog uzglobljenog segmenta, integrirani i zaštićemi unutar cjevaste strukture.
The oral controlled release pharmaceutical composition for use according to claim 1 is used for the treatment of traveler's diarrhea caused by E. coli. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da je za uporabu u liječenju putnih proljeva kojima je uzročnik E. coli.
The mobile station apparatus according to any of claims 1 to 12, wherein DVRBs with non-consecutive DVRB numbers are mapped to two of the PRBs that are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
A bispecific antibody according to the invention containing a common light chain that at least comprises the CDR sequences of 012 is therefore provided. 
VIVSE, i pri čemu obje grane sadrže zajednički laki lanac koji sadrži varijabilnu sekvencu lakog lanca koja se sastoji od sekvence identičnoj s DIG TOSPSSLSBASVGDRVITTCRASQSISSTILNWYGQRPGRAPELUIVAASSLGSGVP